|
|
Il s’agit du premier médicament d’association à doses fixes par voie orale approuvé qui cible deux voies de signalisation majeures liées aux NVIC en associant dans la même gélule le nétupitant, un antagoniste des récepteurs NK1, et le palonosétron, un antagoniste des récepteurs 5-HT3, pour prévenir les NVIC.
|
|
|
AKYNZEO™ (netupitant/palonosetron hydrochloride), in combination with dexamethasone, is indicated for once per-cycle treatment in adult patients for the prevention of acute delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy as well as for the prevention of acute nausea and vomiting associated with moderately emetogenic cancer therapy that is uncontrolled by a 5-HT3 receptor antagonist alone. It is the first approved fixed dose oral combination agent that targets two critical signaling pathways associated with CINV by combining netupitant, an NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist, in a single capsule for the prevention of CINV. The most common adverse events reported with AKYNZEO™ in clinical trials were headache (3.6%), constipation (3.0%) and fatigue (1.2%)i.
|
